Investors in Science

Spinnvest has been operating since 2011 in the field of venture capital investment, focusing on the financing of the start-up and early development phases of innovative startups. From over ten years of experience in supporting the birth and development of innovative startups, Spinnvest also offers services for the management of innovation processes, according to models of open innovation.

Medicxi is a leading investment firm specializing in the life sciences sector. They are dedicated to supporting innovation and advancement in biotechnology, pharmaceuticals, and healthcare. Medicxi collaborates with pioneering entrepreneurs and talented management teams to accelerate the development of breakthrough therapies, medical technologies, and healthcare solutions. With a strategic focus on early and late-stage investments, Medicxi aims to address significant medical challenges and improve patient outcomes globally. Their team combines deep scientific and investment expertise to identify promising opportunities and provide critical support throughout the growth phases of portfolio companies.

AI Seed is uniquely positioned to support AI startups, led by founders who have successfully built and sold their own companies. They specialize in providing tailored support to help AI founders achieve their vision, offering access to top AI entrepreneurs worldwide, assistance in acquiring AI talent, introductions to commercial partners and customers within the AI sector, and comprehensive business mentoring to facilitate scaling and growth. AI Seed's expertise lies in understanding and meeting the specific needs of AI startups, aiming to foster innovation and accelerate success in the field of artificial intelligence.

Monograph Capital is a venture firm focused on life sciences. With a dedicated emphasis on the life sciences sector, Monograph Capital invests in innovative companies and technologies that aim to advance healthcare and biotechnology. The firm supports early-stage ventures as well as growth-stage companies, providing critical capital, strategic guidance, and industry expertise to drive their development and success. Monograph Capital's investments span across biotech, pharmaceuticals, medical devices, and other areas within the life sciences field, aiming to contribute to breakthrough discoveries, therapies, and medical advancements. Through its strategic investments, Monograph Capital plays a crucial role in accelerating innovation and improving health outcomes globally.

BOM Brabant Ventures is the venture capital arm of Brabant Development Agency (BOM), focusing on investments in innovative companies across the Dutch province of North Brabant. As a regional development agency, BOM Brabant Ventures plays a vital role in supporting the growth and competitiveness of local businesses. The firm targets early-stage and growth-stage companies operating in sectors such as high-tech systems & materials, life sciences & health, agri-food, and sustainable energy. BOM Brabant Ventures provides financial investment, strategic guidance, and access to its extensive network of partners and industry experts to help startups scale their operations and enter new markets. By fostering innovation and entrepreneurship, BOM Brabant Ventures contributes to the economic development of North Brabant, creating job opportunities and stimulating technological advancements. The firm also collaborates closely with other regional and national stakeholders to strengthen the innovation ecosystem and attract talent and investment to the region.

NJF Capital is the venture capital arm of NJF Holdings, founded by entrepreneur turned investor Nicole Junkermann. Specializing in venture capital investments, NJF Capital focuses on supporting innovative startups and high-growth companies across various sectors. With a strategic approach to investment, NJF Capital leverages Nicole Junkermann's entrepreneurial background and expertise to identify and nurture promising ventures, aiming to drive impactful growth and success in the global market.

Break Off Capital is a unique investment firm dedicated to directing human and financial resources towards advancing emerging technologies that address significant global challenges. Their focus is on supporting innovations that improve quality of life today and contribute to future generations' progress. Break Off Capital aims to foster technological advancements that have the potential to make a meaningful impact on society and drive positive change worldwide.

The Dementia Discovery Fund is the largest family of specialized venture capital funds dedicated exclusively to investing in companies developing novel therapeutics for dementia. Focused on addressing the urgent need for effective treatments, the fund supports innovative startups and ventures pioneering new approaches in dementia research and therapeutics. By providing strategic investment and industry expertise, the Dementia Discovery Fund aims to accelerate the development of groundbreaking therapies that have the potential to significantly impact patients' lives worldwide.

Oxford Science Enterprises is a venture firm partnered with universities, specializing in early-stage investments across life sciences, AI & software, and deep technology sectors. The firm leverages its close ties with academia to identify and support innovative startups with transformative potential. Oxford Science Enterprises provides strategic capital and operational expertise to help these ventures navigate their early growth phases and achieve market leadership. By focusing on cutting-edge technologies and scientific advancements, the firm aims to drive significant innovation and impact in global markets.

O2h Ventures is an investment firm specializing in biotechnology, providing investors with opportunities to support promising medical innovations through the EIS (Enterprise Investment Scheme) and SEIS (Seed Enterprise Investment Scheme). Focused on backing groundbreaking biotech ventures, O2h Ventures facilitates investments that contribute to advancements in healthcare and medical science, leveraging tax-efficient investment schemes to enhance potential returns for investors.

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. The Aescap Life Sciences and Aescap Genetics funds invest in highly innovative publicly traded biotech/life sciences companies. These companies are developing tomorrow’s medicines. Investing in Aescap funds offers the possibility to achieve excellent returns over the medium term, without taking large risks. Both funds have a focused portfolio, based on deep fundamental analyses and a strict buy and sell discipline. The Aescap funds act under the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR) and operate under a AIFM license.

BioGeneration Ventures (BGV) is a venture capital company focused on early-stage European biotech, medtech, and diagnostics companies. With a strong track record of significant financial returns, BGV invests in healthcare innovations and builds world-class teams. The company manages over €100 million, targeting areas where scientific innovation, unmet medical needs, and the potential for significant proof of concept converge. BGV collaborates with founding teams to mature science and build companies, using its expertise to guide progress into clinical trials, leading to successful drug development and value realization for its investors.